Triflusal

Triflusal is an inhibitor of platelet aggregation (IC50s = 48.3 and 693 µM in isolated human whole blood and platelet-rich plasma, respectively). It inhibits production of thromboxane B2 (TXB2, Cay-19030) and 6 keto prostaglandin F1alpha (6-keto-PGF1alpha, Cay-15210) induced by arachidonic acid (Cay-90010, Cay-90010.1, Cay-10006607) with IC50 values of 468 and 339 µM, respectively, in isolated human whole blood. Triflusal decreases IgG-ovalbumin immune complex-induced NF-kappaB nuclear translocation and production of nitric oxide (NO) in isolated rat peritoneal macrophages when used at a concentration of 1,000 µM. Oral administration of triflusal (30 mg/kg) reduces infarct volume and peri-infarct levels of OX-6, a marker of activated microglia, in a rat model of focal ischemia induced by permanent middle cerebral artery occlusion (MCAO). It also reduces increases in cortical amyloid-beta precursor protein (APP) levels induced by intracerebroventricular administration of amyloid-beta (25-35) in rats at the same dose.Formal Name: 2-(acetyloxy)-4-(trifluoromethyl)-benzoic acid. CAS Number: 322-79-2. Synonyms: UR 1501. Molecular Formula: C10H7F3O4. Formula Weight: 248.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml. lambdamax: 224 nm. SMILES: OC(C1=C(OC(C)=O)C=C(C(F)(F)F)C=C1)=O. InChi Code: InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16). InChi Key: RMWVZGDJPAKBDE-UHFFFAOYSA-N.